FDA clears vepdegestrant, a first-in-class PROTAC, for ESR1-mutated breast cancer

The US Food and Drug Administration approved vepdegestrant on 1 May 2026 for a defined slice of advanced breast cancer, making it the first drug of a new class — a PROTAC, or proteolysis-targeting chimera — to reach the market [s2]. The clearance covers oestrogen-receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer that has progressed after at least one line of endocrine therapy, and it rests on the phase 3 VERITAC-2 trial, in which the drug more than doubled median progression-free survival over standard fulvestrant in patients carrying an ESR1 mutation [s1][s2].

What makes the approval notable beyond breast cancer is the mechanism. Most cancer drugs block a protein; a PROTAC destroys it. Vepdegestrant, taken as a daily 200 mg tablet, is a two-headed molecule that grabs the oestrogen receptor with one end and an E3 ubiquitin ligase with the other, tagging the receptor for disposal by the cell's own protein-shredding machinery, the ubiquitin–proteasome system [s1][s2]. The oestrogen receptor is the engine of the most common form of breast cancer, and destroying it rather than merely blocking it is a strategy drug developers have pursued for years without a marketed product to show for it — until now.

What the trial did

VERITAC-2 was a phase 3, open-label, randomised trial that enrolled 624 patients with ER-positive, HER2-negative advanced breast cancer who had already received one line of a CDK4/6 inhibitor plus endocrine therapy [s1]. They were assigned 1:1 to vepdegestrant, 200 mg orally once a day, or fulvestrant, 500 mg by intramuscular injection on the standard schedule; 313 received the new drug and 311 the comparator [s1]. Randomisation was stratified by ESR1-mutation status and by whether the cancer had spread to internal organs [s1].

The design carried a built-in caution that matters for reading the result: the primary endpoint of progression-free survival was tested both in the subgroup with ESR1 mutations and in the whole randomised population [s1]. ESR1 mutations are acquired resistance changes that arise under the pressure of prior endocrine therapy and that blunt drugs like fulvestrant, so they mark the patients in whom a better degrader would be expected to help most — and the ones on whom the eventual label was written [s1][s2].

What it found

Among the 270 patients with an ESR1 mutation, median progression-free survival was 5.0 months (95% confidence interval 3.7 to 7.4) with vepdegestrant versus 2.1 months (95% CI 1.9 to 3.5) with fulvestrant, a hazard ratio of 0.58 (95% CI 0.43 to 0.78; P<0.001) [s1]. In the full trial population, the gap all but vanished: 3.8 months (95% CI 3.7 to 5.3) versus 3.6 months (95% CI 2.6 to 4.0), a hazard ratio of 0.83 (95% CI 0.69 to 1.01; P=0.07) that did not reach statistical significance [s1].

That split is the whole story. The drug's advantage was real and roughly a doubling of median PFS, but confined to the biomarker-defined group; in patients without an ESR1 mutation, it performed no better than an injection that has been on pharmacy shelves for two decades [s1]. Grade 3 or higher adverse events occurred in 23.4% of the vepdegestrant group and 17.6% of the fulvestrant group, and treatment was stopped for adverse events in 2.9% and 0.7% respectively — a modestly higher toxicity burden for the oral drug [s1].

How to read it

Two numbers frame the honest verdict. The 0.58 hazard ratio in the ESR1 subgroup is a clear win over fulvestrant, and it is why the FDA restricted the indication to patients with the mutation, detected by an authorised test [s1][s2]. But an absolute median gain of 2.9 months is incremental, not transformative, and fulvestrant is itself a weak comparator that many oncologists no longer consider a preferred option in this setting — so the trial answers whether vepdegestrant beats fulvestrant, not whether it beats the newer oral agents now competing for the same patients [s1].

The approval's significance is therefore as much about the platform as the effect size. If a PROTAC can be dosed orally, cleared through regulatory review and shown to work in a randomised trial, the door opens for targeted degraders against proteins that have resisted conventional drugs. The immediate clinical question — where a daily degrader sits among the endocrine options for ESR1-mutated disease — is narrower, and it turns on head-to-head data the trial did not generate.

The direct comparison it invites is with another ESR1-targeted strategy already covered here: the next-generation oral SERD camizestrant, tested in SERENA-6's blood-test-guided switch design, which attacks the same resistance mutation from a different angle.

Why it matters

ESR1 mutations are one of the best-characterised routes by which hormone-driven breast cancer escapes treatment, and matching a drug to that mutation is exactly the kind of biomarker-defined targeting that modern oncology is built on. Vepdegestrant's approval validates both a specific target and a general chemistry. It does not make the drug a default, and the modest full-population result is a reminder that a first-in-class label is not the same as a first-choice therapy.

What to watch

The near-term questions are practical: uptake against the competing oral SERDs, the cost of companion ESR1 testing, and whether ongoing trials pairing vepdegestrant with CDK4/6 inhibitors move it earlier in treatment, where a larger absolute benefit might emerge [s1][s2]. Longer term, the more consequential watch is whether other PROTACs follow it through the clinic now that the class has cleared the regulatory bar for the first time.

This article describes research and regulatory developments and is not medical advice. Treatment decisions are for patients and their treating clinicians.

Sources

• Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer — New England Journal of Medicine, online 31 May 2025 (VERITAC-2)
• Drugs@FDA: Veppanu (vepdegestrant), NDA 219835 — original approval — U.S. Food and Drug Administration, approved 1 May 2026